1/18/2024 0 Comments Moderna side effect facial fillerOf the 343 patients with cutaneous manifestations, only reactions to the first dose were recorded for 215 (63%) patients, of whom 203 (94%) planned to receive the second dose and 12 (5.6%) did not plan to receive the second dose due to concerns regarding their first-dose cutaneous reactions. The most common cutaneous reactions were delayed large local reactions (n = 175 first n = 31 second dose), local injection site reaction (n = 117 first dose n = 69 second dose), urticaria (n = 16 first dose n = 7 second dose), morbilliform (n = 11 first dose 7 second dose), and erythromelalgia (n = 5 first dose n = 6 second dose Table II There were 343 unique reports of cutaneous manifestations after the Moderna vaccination, including 267 reported after the first dose and 102 reported after the second dose. All other photos follow individual patients' reaction after vaccine dose 1 and dose 2. ∗Different patient photos are used for local site injection reaction photos. No patient experienced anaphylaxis or another severe adverse event after the second COVID-19 vaccine dose. The Massachusetts General Brigham Institutional Review Board exempted this study as not human subject research.Ī depiction of the characteristics of the subset of patients who experienced the same dermatologic finding after both the first and second COVID-19 vaccine doses. We used Stata version 16 (StataCorp, LLC) to descriptively analyze data. ![]() We excluded records where the provider was ultimately unable to provide key variables (eg, vaccine brand or those in which vaccine dose elicited a reaction). We contacted providers who entered partially completed records and asked them to complete all fields. All respondents who only entered a cutaneous reaction to the first vaccine dose were sent a follow-up email to solicit the presence/absence of a cutaneous reaction to the second vaccine dose. Both vaccines require 2 doses administered 3-4 weeks apart. We only included cutaneous reactions reported after vaccination with Food and Drug Administration-approved Pfizer or Moderna mRNA vaccines, which at the time of analysis were being administered mostly to health care workers and elderly patients. ![]() 4 Conversely, urticarial reactions were defined as wheals in a distribution beyond the injection site. A wheal at the vaccine site was considered an immediate or delayed large local reaction, depending on timing. ![]() Local site reactions were defined as occurring within 3 days of first-dose vaccination and delayed large local reactions were defined as occurring 4 or more days after the first vaccination. The vaccine module of the registry collected dates for both vaccine doses, morphology of cutaneous reaction(s), timing and duration of reaction(s), and treatments. Our international registry of cutaneous manifestations of SARS-CoV-2, established in March 2020 as a collaboration between the American Academy of Dermatology and the International League of Dermatological Societies, expanded on December 24, 2020, to collect COVID-19 vaccine cutaneous reactions, shortly after the Food and Drug Administration issued Emergency Use Authorizations ( 3 Case entry in the registry was open to health care workers only. ![]() Given the importance of widespread vaccination in curbing the pandemic, we aimed to collect cases of cutaneous side effects to the messenger RNA (mRNA) COVID-19 vaccines (1) to describe the morphology and timing of cutaneous reactions to the Pfizer and Moderna vaccines and (2) to understand differences in cutaneous reactions between the 2 vaccine doses to guide vaccine counseling. 1 However, trials did not fully characterize cutaneous reactions and did not describe whether subjects with reactions after the first dose also had reactions with the second. 1 Moderna's trial also described vesicular, urticarial, exfoliative, macular, and papular rashes, as well as facial swelling after cosmetic filler injections. 1, 2 Moderna additionally noted delayed injection site reactions (on/after day 8) in 244 participants (0.8%) after the first dose and in 68 participants (0.2%) after the second dose. In December 2020, the Food and Drug Administration issued Emergency Use Authorizations for Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-1273) COVID-19 vaccines.Ĭlinical trials for both vaccines reported local injection site reactions and systemic symptoms after both doses.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |